Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.38. Hemispherx BioPharma shares last traded at $0.37, with a volume of 97,954 shares trading hands.
Hemispherx BioPharma Trading Down 1.9 %
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
- Five stocks we like better than Hemispherx BioPharma
- Top Biotech Stocks: Exploring Innovation Opportunities
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Brinker International Offers a Pullback Opportunity on EPS Miss
- What is the FTSE 100 index?
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.